Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results

Allergen (AGN) PT Lowered to $200 at Mizuho Securities

January 30, 2019 8:21 AM EST

Mizuho Securities analyst Irina Koffler lowered the price target on Allergen (NYSE: AGN) to $200.00 (from $213.00) while maintaining a Buy rating. Mizuho Securities raised our 2019 revenue from $15.0B to $15.1B due to continued Restasis durability in 1Q:19. Koffler also slightly lowered the tax rate (to... More

Allergan (AGN) in Final Stages of Selling Antibiotics Divisions, Plans to Keep Women's Health Unit - Bloomberg, Citing Conf. Call

January 29, 2019 8:43 AM EST

Allergan (NYSE: AGN) in Final Stages of Selling Antibiotics Divisions, Plans to Keep Women's Health Unit - Bloomberg, Citing Conf. Call

... More

Allergan (AGN) Tops Q4 EPS by 14c, Offers Q1 and FY Guidance, Approves $2B Buyback

January 29, 2019 7:04 AM EST

(Updated - January 29, 2019 7:12 AM EST)

Allergan (NYSE: AGN) reported Q4 EPS of $4.29, $0.14 better than the analyst estimate of $4.15. Revenue for the quarter came in at $4.08 billion versus the consensus estimate of $4 billion.

GUIDANCE:

Allergan sees FY2019 EPS of at least... More